文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

美国2011-2016年耐多药结核病短程治疗方案资格评估

Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究评估了美国2011-2016年报告且具有完整药敏试验结果的耐多药结核病病例对WHO短程治疗方案的资格。在586例报告病例中,仅10%(59例)符合资格。实施短程方案将使美国年度社会成本负担降低4%,但符合资格个体的成本降低37-46%。

要点

  • 美国耐多药结核病患者中仅少数符合WHO短程方案资格。
  • 不符合资格的主要原因是乙胺丁醇和吡嗪酰胺耐药。
  • 短程方案对社会成本降低有限,但对个体成本降低显著。

核心结论

  • 基于完整药敏试验,美国少数耐多药结核病患者符合短程方案资格。
  • 短程方案对社会的成本降低很小,但对符合资格个体的成本降低很大。

研究设计与样本

  • 研究评估了2011-2016年向美国国家结核病监测系统报告且具有完整药敏试验结果的耐多药结核病病例。
  • 共纳入586例报告病例,其中527例不符合短程方案资格。
  • 成本估算基于先前一项基于人群的研究中的住院和门诊成本比例。

主要发现

  • 586例报告病例中,10%(59例)符合短程方案资格。
  • 527例不符合资格的患者中,386例具有完整药敏试验,其中246例对乙胺丁醇耐药,217例对吡嗪酰胺耐药。
  • 与常规耐多药结核病治疗相比,实施短程方案将使美国年度社会成本负担降低4%,符合资格个体的成本负担降低37-46%。

关键数值与推荐

  • WHO短程方案(9-12个月)资格标准:无肺外结核、无妊娠、无既往二线抗结核药物暴露、对吡嗪酰胺、乙胺丁醇、卡那霉素、莫西沙星、乙硫异烟胺或氯法齐明敏感。

临床怎么用

  • 在资源丰富地区,应用短程方案前需评估完整药敏试验结果以确定资格。
  • 短程方案可显著降低符合资格个体的治疗成本,但对社会总体成本影响有限。

局限性

  • 成本估算基于先前研究中的住院和门诊成本比例,可能存在不确定性。
  • 研究仅纳入具有完整药敏试验结果的病例,可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2016, the World Health Organization (WHO) recommended a shorter (9-12 month) multidrug-resistant tuberculosis (MDR-TB) treatment regimen (as compared to the conventional 18-24 month regimen) for patients without extrapulmonary TB, pregnancy, a previous second-line TB medication exposure, or drug resistance to pyrazinamide, ethambutol, kanamycin, moxifloxacin, ethionamide, or clofazimine. The recommendation was based on successful clinical trials conducted in Asia and Africa, but studies, using mainly European data, have shown few patients in higher-resource settings would meet WHO eligibility criteria. METHODS: We assessed eligibility for the shorter regimen among US MDR-TB cases that had full drug susceptibility testing (DST) results and were reported during 2011-2016 to the US National TB Surveillance System. We estimated costs by applying the eligibility criteria for the shorter regimen, and proportional inpatient/outpatient costs from a previous, population-based study, to all MDR-TB patients reported to the National TB Surveillance System. RESULTS: Of 586 reported MDR-TB cases, 10% (59) were eligible for the shorter regimen. Of 527 ineligible patients, 386 had full DST, of which 246 were resistant to ethambutol and 217 were resistant to pyrazinamide. Compared with conventional MDR-TB treatment, implementing the shorter regimen would have reduced the US annual societal MDR-TB cost burden by 4%, but the cost burden for eligible individuals would have been reduced by 37-46%. CONCLUSIONS: Relying on full DST use, our analysis found a minority of US MDR-TB patients would have been eligible for the shorter regimen. Cost reductions would have been minimal for society, but large for eligible individuals.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tsang CA, Shah N, Armstrong LR, et al. Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016. Clin Infect Dis. 2020. PMID: 30944927. doi:10.1093/cid/ciz263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。